TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28889155

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided transversus abdominis plane (TAP) block, 0.3 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ilio‐inguinal/ilio‐hypogastric (II/IH) block, 0.7 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caudal block, 0.5 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Number of subjects: 90
Study: 26086986

Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 35
Study: 24402390

Group type: EXPERIMENTAL
Intervention: Individual dietary counseling as part of a Comprehensive Geriatric Assessment
Number of subjects: 173
Study: 21594236

Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Variolink cement on non-aged composites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Variolink cement on non-aged composites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Panavia F2.0 cement on aged composites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Panavia F2.0 cement on aged composites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Indirect composite (Estenia) with Variolink cement on aged composites
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pressed glass ceramic (IPS Empress II) with Variolink cement on aged composites
Number of subjects: 160

Group type: COMPARATOR
Intervention: Overall comparison of indirect composite and pressed glass ceramic
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Failure types in indirect resin composite substrate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Failure types in ceramic substrate
Number of subjects: 160
Study: 19667022

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone induction therapy followed by glatiramer acetate (GA)
Number of subjects: 0
Study: 22093991

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (2 × 15 mg for 1st postoperative 24 h; 2 × 10 mg for 2nd postoperative 24 h), paracetamol & tramadol hydrochloride tablets (8 × 1 tablet for postoperative 48 h) orally plus pethidine injection on demand (OXY group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with 0.1% ropivacaine, 0.1 µg/ml sufentanil plus injected pethidine on demand (EDA group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (OXY group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (EDA group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16006443

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 895
Study: 12042673

Group type: EXPERIMENTAL
Intervention: MTHFR 1298CC genotype
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Combined heterozygosity of MTHFR 677C>T and 1298A>C polymorphisms
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: MTHFR 1298A>C polymorphism
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: MTHFR 677C>T polymorphism
Number of subjects: 554
Study: 10073777

Group type: EXPERIMENTAL
Intervention: Ramp protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Step protocol (Bruce or modified Bruce)
Number of subjects: 24
Study: 7793221

Group type: EXPERIMENTAL
Intervention: Propofol (2.0 mg.kg‐1) followed by low dose (6 mg.kg‐1.h‐1) infusion
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propofol (2.0 mg.kg‐1) followed by high dose (12 mg.kg‐1.h‐1) infusion
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methohexital (1.5 mg.kg‐1) followed by low dose (5 mg.kg‐1.h‐1) infusion
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Methohexital (1.5 mg.kg‐1) followed by high dose (10 mg.kg‐1.h‐1) infusion
Number of subjects: 35
Study: 2286598

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for seven days
Number of subjects: 282

Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for seven days
Number of subjects: 282
Study: 7291971

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (5000 units 8 hourly)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 100
Study: 29274831

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g) preoperatively
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 105
Study: 27923244

Group type: EXPERIMENTAL
Intervention: Prestationary intervention
Number of subjects: 317

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 317
Study: 23360695

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention based on Pender's Health Promotion Model
Number of subjects: 100
Study: 22897518

Group type: EXPERIMENTAL
Intervention: Studied Swahili-Swedish word pairs four times
Number of subjects: 0

Group type: COMPARATOR
Intervention: Studied (two times) and performed delayed JOLs (two times) alternately
Number of subjects: 0
Study: 20571133

Group type: EXPERIMENTAL
Intervention: Peer-based culturally competent person-centered care
Number of subjects: 0
Study: 18490495

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Aliskiren 1200 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Aliskiren (both doses)
Number of subjects: 298
Study: 15941879

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 100
Study: 12609640

Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 444

Group type: COMPARATOR
Intervention: E-mail contact
Number of subjects: 444
Study: 10485152

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 32
Study: 7594019

Group type: EXPERIMENTAL
Intervention: American patients with prior symptoms of heart disease
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Canadian patients with prior symptoms of heart disease
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Patients without prior symptoms of heart disease (both Americans and Canadians)
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Patients with prior symptoms of heart disease (Americans)
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Patients with prior symptoms of heart disease (Canadians)
Number of subjects: 1212
Study: 1951617

Group type: EXPERIMENTAL
Intervention: Most-preferred tasks under nonpurposeful conditions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Least-preferred tasks under nonpurposeful conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Most-preferred tasks under purposeful conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Least-preferred tasks under purposeful conditions
Number of subjects: 20
Study: 7027827

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: etidocaine 1%
Number of subjects: 15

Group type: COMPARATOR
Intervention: physiologic saline
Number of subjects: 15
Study: 31076476

Group type: EXPERIMENTAL
Intervention: Allergy testing (structured allergy history and skin prick tests)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 29898030

Group type: EXPERIMENTAL
Intervention: Topical Erythropoietin (EPO) - 1 mL of gel containing erythropoietin at a concentration of 4,000 IU mL‐1 applied to the donor site
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control - 2 mL of gel alone applied to the donor site
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical Erythropoietin (EPO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 27175708

Group type: EXPERIMENTAL
Intervention: Gum elastic bougie (GEB)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Bougie combined with cricoid displacing (BCD)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 78
Study: 24811228

Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous exchange (CAVE) technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional pull-push (PP) technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CAVE technique
Number of subjects: 22

Group type: COMPARATOR
Intervention: PP technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CAVE and PP techniques
Number of subjects: 22
Study: 22421389

Group type: EXPERIMENTAL
Intervention: Transbuccal plate fixation
Number of subjects: 261

Group type: COMPARATOR
Intervention: Intraoral external oblique ridge plate fixation
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 261
Study: 20955402

Group type: EXPERIMENTAL
Intervention: Standard care with Arginine Butyrate administered 5 d/week for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard local care alone (Control Arm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standard care with Arginine Butyrate
Number of subjects: 27
Study: 18573198

Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mucosal advancement flap
Number of subjects: 60
Study: 15751606

Group type: COMPARATOR
Intervention: Testosterone treatment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CDGP
Number of subjects: 151
Study: 12494286

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9652880

Group type: COMPARATOR
Intervention: Captopril 75 mg/d and placebo (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Captopril 75 mg/d plus losartan 12.5 mg (first dose), then 25 mg/d (Group B)
Number of subjects: 44
Study: 8587088

Group type: EXPERIMENTAL
Intervention: Super Malic (200 mg malic acid and 50 mg magnesium, 3 tablets bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Super Malic (up to 6 tablets bid) during open label trial
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2655501

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (1 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrathecal methadone (1 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 773068

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (Dexon)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Silk
Number of subjects: 326
Study: 29369265

Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support Systems (CCDSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No further intervention (comparison arm)
Number of subjects: 50
Study: 30536185

Group type: EXPERIMENTAL
Intervention: Topical sodium hyaluronate (SH) 0.18%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (DMC)
Number of subjects: 30
Study: 28087423

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery pulsatility index at inclusion
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery pulsatility index Z-score at inclusion
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Umbilicocerebral ratio Z-score at inclusion
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Gestation at delivery
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Birthweight p50 ratio
Number of subjects: 374
Study: 25604134

Group type: EXPERIMENTAL
Intervention: Erlotinib 25 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study: 23247737

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 63
Study: 21879897

Group type: EXPERIMENTAL
Intervention: Active ITD
Number of subjects: 8718

Group type: COMPARATOR
Intervention: Sham ITD
Number of subjects: 8718
Study: 19164850

Group type: EXPERIMENTAL
Intervention: Coupled bilateral training with a load on the unimpaired hand
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coupled bilateral training with no load on the unimpaired hand
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no stimulation assistance or load)
Number of subjects: 30
Study: 17101557

Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2D echocardiography
Number of subjects: 34

Group type: COMPARATOR
Intervention: ECG (Sokolow-Lyon)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ECG (Cornell)
Number of subjects: 34
Study: 15359398

Group type: EXPERIMENTAL
Intervention: Preincisional wound infiltration of 3 mg/kg ropivacaine (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Postincisional wound infiltration of 3 mg/kg ropivacaine (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Group III) - no local anesthetic
Number of subjects: 45
Study: 11512129

Group type: EXPERIMENTAL
Intervention: Fixed-value mean imputation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard complete data formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood based analyses
Number of subjects: 0
Study: 9709393

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 6 breaths/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 10 breaths/min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 16 breaths/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chronic metoprolol treatment
Number of subjects: 14
Study: 7976801

Group type: EXPERIMENTAL
Intervention: dimethindene maleate (new 'once a day formulation')
Number of subjects: 18

Group type: COMPARATOR
Intervention: loratadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 2596365

Group type: EXPERIMENTAL
Intervention: Gestoden triphasic formulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fixed dose combination pill containing desogrestrel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gestoden triphasic formulation and Fixed dose combination pill containing desogrestrel
Number of subjects: 30
Study: 5440571

Group type: EXPERIMENTAL
Intervention: Oral lignocaine (500 mg taken with food)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral lignocaine (500 mg taken without food)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral lignocaine
Number of subjects: 4
Study: 30772830

Group type: EXPERIMENTAL
Intervention: BLS training conducted by emergency physicians
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: BLS training conducted by medical students
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Interim retesting
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (no interim retesting)
Number of subjects: 460
Study: 28177740

Group type: EXPERIMENTAL
Intervention: 5:40 (24 × 5‐s bouts, 40‐s recovery)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15:120 (8 × 15‐s bouts, 120‐s recovery)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30:240 (4 × 30‐s bouts, 240‐s recovery)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CTRL (resting control session)
Number of subjects: 9
Study: 26448381

Group type: EXPERIMENTAL
Intervention: Oral alfacalcidol therapy for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 non-diabetic HD patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (12 healthy subjects)
Number of subjects: 20
Study: 24475554

Group type: EXPERIMENTAL
Intervention: Laryngoscopy (Group A, n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA) (Group B, n=17)
Number of subjects: 34
Study: 21551374

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study: 18819792

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m(2) intravenous (i.v.) on days 1 and 8 of each 21‐day cycle
Number of subjects: 21
Study: 16822100

Group type: EXPERIMENTAL
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 36
Study: 14518352

Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate treatment for three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10090430

Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered to patients undergoing coronary angioplasty; monitored for anti-eptifibatide antibodies at baseline and 30 days after treatment.
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered to 28 healthy volunteers; 2 infusions 28 days apart, monitored at multiple time points (baseline, 28, 42, 56, 84, and 112 days).
Number of subjects: 442
Study: 7672152

Group type: EXPERIMENTAL
Intervention: Single IM injection of 100 mg progestogen (group 1)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No progestogen (group 2)
Number of subjects: 49
Study: 2198069

Group type: EXPERIMENTAL
Intervention: Normal elderly adults
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal young adults
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dysarthric subjects
Number of subjects: 40
Study: 7032947

Group type: EXPERIMENTAL
Intervention: Atenolol (50, 100, and 200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 10
Study: 6585544

Group type: EXPERIMENTAL
Intervention: Topical steroidal gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo gel and capsules (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sulindac (systemically administered nonsteroidal anti-inflammatory drug)
Number of subjects: 18
Study: 30894009

Group type: EXPERIMENTAL
Intervention: Group B (dual-energy spectral imaging with reduced contrast dose at 0.3 gI/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group A (conventional 120kVp scanning protocol with contrast dose at 0.6 gI/kg)
Number of subjects: 41
Study: 29973437

Group type: EXPERIMENTAL
Intervention: Calcium alginate (Ca-Alg) 5%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium alginate (Ca-Alg) 8%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Udon noodles without Ca-Alg
Number of subjects: 15
Study: 27488692

Group type: EXPERIMENTAL
Intervention: On-site support (OSS)
Number of subjects: 36
Study: 24881806

Group type: COMPARATOR
Intervention: Standard urotherapy treatment alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standard urotherapy + TENS
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standard urotherapy + TENS (in children without previous treatment)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard urotherapy (in children without previous treatment)
Number of subjects: 62
Study: 23043295

Group type: EXPERIMENTAL
Intervention: Garlic oil (0.005 mL/L) and ginger oil (0.005 mL/L) mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Garlic oil (0.005 or 0.01 mL/L) and ginger oil (0.005 or 0.01 mL/L) mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Garlic oil (0.02 mL/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginger oil (0.01-0.02 mL/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Garlic oil or garlic oil-ginger oil mixture
Number of subjects: 0
Study: 20528680

Group type: EXPERIMENTAL
Intervention: Empowered patient
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Computer decision support system (CDSS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 18586224

Group type: EXPERIMENTAL
Intervention: Self-generation strategy (generated condition)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Provided condition (control)
Number of subjects: 38
Study: 17469416

Group type: EXPERIMENTAL
Intervention: Surgical sphincteroplasty of the minor papilla
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic stent placement and/or minor papilla endoscopic papillotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic management of symptomatic patients with PD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRCP
Number of subjects: 0
Study: 11811168

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 44

Group type: COMPARATOR
Intervention: Drink test
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nepean Dyspepsia Index symptoms
Number of subjects: 44
Study: 10089089

Group type: EXPERIMENTAL
Intervention: Piperacillin 12 g/day plus tazobactam 1.5 g/day plus tobramycin 3 mg/kg per day
Number of subjects: 247

Group type: COMPARATOR
Intervention: Ceftazidime 3 g/day plus tobramycin 3 mg/kg per day
Number of subjects: 247
Study: 7589035

Group type: EXPERIMENTAL
Intervention: RS-86505-007 3 micrograms t.i.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RS-86505-007 6 micrograms t.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: RS-86505-007
Number of subjects: 50
Study: 2405739

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17201

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17201
Study: 6930207

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous heparin
Number of subjects: 0